УДК 617.736-002.16-053.9-073-08

https://doi.org/10.31288/oftalmolzh2013493109

Новітні принципи діагностики та лікування вікової дегенерації макули

Н. В. Пасєчнікова, член-корр. НАМИ України, проф., д.мед.н., А. Р. Король, к. мед. н., О. С. Задорожний, к. мед. н., Т. Б. Кустрин, І. О. Насінник

ДУ «Інститут очних хвороб і тканинної терапії ім. В. П. Філатова НАМН України»

References

1.Balashevich L. I. Creation and investigation of effectiveness of argon and diode laser application in pathology of eye fundus: author's abstract: 14.01.07 Eye diseases. St.Petersburg; 1996. 35 p.

2.Basinskii SN, Krasnogorskaya VN. A new method for treatment of atherosclerotic-related macular degeneration. Vestn Oftalmol. 1997; 6:17-9. Russian.

3.Guzun OV, Linnik LA, Ponomarchuk VS. Therapeutic ef-ficacy of low-intensity radiation of the two-wavelength semiconductor laser of red and near-infrared spectrum in patients with atherosclerotic central chorioretinal dystrophy. Oftalmol Zh. 2001; 6: 14-8. Russian.

4.Dzhaliashvili OA, Klyavina AE, Suhotu NH. Intravazal and ultraviolet irradiation of autoblood in the treatment of central chorioretinal nonexudative dystrophy. Vestn Oftalmol. 1990; 1: 41-3. Russian.

5.Eliseeva EG. Argon laser in treatment of hemorrhagic de-tachment of the macula pigment epithelium. IV All Russian congress of ophthalmologists: Proceedings. Moscow; 1982: 340-1. Russian.

6.Eliseeva EG, Pereverzina OK, Simonova KK. Laser therapy for cystic maculopathy with false openings. Rekonstruk-tivnaia oftalmokhirurgiia. Moscow; 1979. 147- 50.

7.Ivanishko YuA. Laser methods of treatment of macular area of the retina: author's thesis. Rostov-on-Don; 1992 38 p.

8.Katsnelson LA. Prevention and dispensary treatment of vascular disease of the eye. Vestn Oftalmol. 1985; 6: 5-8. Russian.

9.Katsnelson LA, Agranovich MS, Ivanova LI. Etiology and pathogenesis of central chorioretinal discoid dystrophy. 1982; 1: 19-21. Russian.

10.Katsnelson LA, Lysenko VS, Balishanskaya TI. Clinical atlas of eye fundus pathology. Moscow: GEOTAR Medit-sina; 1998. 151 p.

11.Katsnelson LA, Makarskaya NV, Forofonova TN. On laser stimulation in the in central retinal dystrophies. VII republic conference of Lithuanian SSR: abstract book. Kaunas; 1980. 25-26.

12.Katsnelson LA, Forofonova TN, Bunin AYa. Vascular dis-eases of the eye. M.: Meditsina; 1990. 268 p.

13.Krasnov MM, Bolshunov AV, Ziangirova GG, Pivovarov NN. On the so-called laser stimulation of the macula and the possible theoretical interpretation of the mechanism of its therapeutic action. Oftalmol Zh. 1982; 4: 197- 201. Russian.

14.Leus NF, Metelitsina IP, Linnik LA. The action of low-energy radiation of heliumneon laser on the hydrolytic lysosomal enzymes of the retina. Oftalmol Zh. 1986; 2: 126-7. Russian.

15.Linnik LA, Baronetskaya IL. Treatment of central retinal dystrophies with ruby laser subthreshold energy. Oftalmol Zh. 1978; 3: 164-8. Russian.

16.Linnik LA, Usov VYa, Chechin PP et al. Prospects of using laser therapy in ophthalmology. Oftalmol Zh. 1982; 4: 193-7. Russian.

17.Mironova EM, Shilkin GA, Grigoryants TN. The state of the functional activity of the nervous and ocular apparatus, regional blood circulation and ghemohydrodinamicsof the eye in patients with involutional central chorioretinal dystrophy. MNTK «Microsurgery of the eye». M.; 1989. 13.

18.Kharlal SK, Bernekin EB. Using hyperbaric oxygen therapy in patients with lesions of the macular area. Hyperbaric oxygen therapy. M.; 1977. 51-3.

19.Shamshinova AM. Hereditary and congenital diseases of the retina and optic nerve. M.: Meditsina; 2001. 234 p.

20.Age-Related Eye Disease Study Research Group. A randomized, placebocontrolled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Age-Related Eye Disease Study Research Group. Arch. Ophthalmol. 2001; 119: 1417-36.

21.Bird AC, Bressler NM, Bressler SB et al. An International classification and grading for age-related maculopathy and age-related macular degeneration. Surv. Ophthalmol. 1995; 39: 367-74.
Crossref

22.BMPSCC. Argon laser photocoagulation for neovascu-lar maculopathy. BMPSCC. Arch. Ophthalmol. 1986; 5: 694-701.
Crossref

23.Bressler NM, Rosenfeld JM, Lim JI. VIM Study Group. A phase II placebo-controlled, double-masked, randomized trial — Verteporfin In Minimally classic CNV due to AMD (VIM). Invest. Ophthalmol. Vis. Sci. 2003; 44: E-Abstract 1100.

24.Chen JC, Fitzke FW, Pauleikhoff D et al. Functional loss in age-related Bruch's membrane change with choroidal perfusion defect. Invest. Ophthalmol. Vis. Sci. 1992; 33: 334-40.

25.Cleasby GW, Fung WE, Fiore JV. Photocoagulation of exudative senile maculopathy. Arch. Ophthalmol. 1971; 1: 18-26.
Crossref

26.Costa RA, Farah ME, Cardillo JA et al. Photodynamic therapy with indocyanine green for occult subfoveal cho-roidal neovascularization caused by age-related macular degeneration. Curr. Eye Res. 2001; 23: 271-5.
Crossref

27.Costa RA, Meirelles RL et al. Retinal capillary hemangio-ma treatment by indo-cyanine green-mediated phototro-mbosis. Amer. J. Ophthalmol. 2003; 135: 395- 8.
Crossref

28.Ferris FL. 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 1984; 102: 1640-2.
Crossref

29.Freyler H. Die Fluoreczenzangiographie als Grundlage einer erfolgreichen Lichtkoagulatien bei diabetischen Ret-inopathie. Klin. Ibl. Augenheilkld. 1978; 2: 182- 95.

30.Friedman E, Ivry M, Bbert E et al. Increased scleral rigidity and age-related macular degeneration. Ophthalmology. 1989; 96(1): 104-8.
Crossref

31.Gass JDM, Jallow S, Davis B. Adult vitelliform macular detachment occuring in patients with basal laminar drusen. Amer. J. Ophthalmol. 1985; 99(4): 445-59.
Crossref

32.Husain D, Kramer M, Kenny AG et al. Effects of photo-dynamic therapy using verteporphin on experimental cho-roidal neovascularization and normal retina and choroids up to 7 weeks after treatment. Invest. Ophtalmol. Vis. Sci. 1999; 40: 2322-31.

33.Kafer O. Makularkrankungen, Degenerative Makula-leiden. Internist. Prax. 1977; 4: 605- 12.

34.L'Esperance FA. Ocular Photocoagulation. A stereoscopic atlas. St. Louis etc. CV Mosby Co; 1983. 605 p.

35.Macular Photocoagulation Study Group. Laser photo-coagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macu-lar Photocoagulation Study Group. Macular Photocoagulation Study Group. Arch. Ophthalmol. 1994; 112: 500-9.
Crossref

36.Macular Photocoagulation Study Group: Subfoveal neo-vascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch. Ophthalmol. 1991; 109(9): 1242- 57.
Crossref

37.Meyer-Betz F. Untersuchung uber die biologische (photo-dynamische) Wirkung des Hamatoporphyrins und anderer Derivate des Blut- und Gallenfarbstoffs. Dtsch. Arch. Klin. Med. 1913; 112: 476- 503.

38.Miller JW, Kramer M et al. Photodynamic therapy of ex-perimental choroidal neovascularization using lipopro-tein-delivered benzoporphyrin. Arch. Ophthalmol. 1995; 113: 810-2.
Crossref

39.Nasemann J. Senile Makuladegeneration. Z. prakt. Augenheilkld. 1988; 7: 575-8.

40.Pierce EA, Avery RL, Foley ED et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Nat. Acad. Sci. USA. 1995; 92: 905-9.
Crossref

41.Reinke MH, Canakis C, Husain D et al. Verteporfin pho-todynamic therapy ret-reatment of normal retina and choroid in the cynomologous monkey. Ibid. — 1999; 106: 1915-23.
Crossref

42.Schmidt-Erfurth U, Bauman W, Gragoudas E et al. Pho-todynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology. 1994; 101(1): 89-99.
Crossref

43.Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.. Ophthalmol. 2000; 45(3): 195-214.
Crossref

44.Schmidt-Erfurth U, Hasan T, Schomacker K et al. In vivo uptake of liposomal benzoporphyrin derivative and pho-tothrombosis in experimental corneal neovascularisation. Lasers Surg. Med. 1995; 17(2): 178- 88.
Crossref

45.Schnurrbusch UE, Welt K, Horn LC et al. Histological findings of surgically excised choroidal neovascular mem-branes after photodynamic therapy. J. Ophthalmol. 2001; 85: 1086 - 91.
Crossref

46.Sickenberg M, Schmidt-Erfurth U, Miller JW et al. A pre-liminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and id-iopathic causes. Arch. Ophthalmol. 2000; 118(3): 327-36.
Crossref

47.Smiddy WE, Fine SL. Prognosis of patients with bilateral macular druzen. Ophthalmology. 1984; 91: 271-7.
Crossref

48.Sorenson JA, Yannuzzi LA, Shakin JL. Recurrent subretinal neovasculariza-tion. Ibid. 1985; 92: 1059- 74.
Crossref

49.The choroidal neovascularization prevention trial research. group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology. 2003; 121: 971-8.